Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

World Portal Hypertension Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 12 Oct 16

Research and Markets has announced the addition of the "Portal Hypertension - Pipeline Review, H2 2016" report to their offering.

Portal Hypertension Portal hypertension is an increase in the blood pressure within a system of veins called the portal venous system. The increase in pressure is caused by a blockage in the blood flow through the liver. Symptoms include ascites, reduced levels of platelets or white blood cells, gastrointestinal bleeding, encephalopathy or confusion and forgetfulness. The most common cause of portal hypertension is cirrhosis or scarring of the liver.

Portal Hypertension pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 1 respectively.

Portal Hypertension - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Portal Hypertension Overview
  3. Therapeutics Development
  4. Pipeline Products for Portal Hypertension - Overview
  5. Pipeline Products for Portal Hypertension - Comparative Analysis
  6. Portal Hypertension - Therapeutics under Development by Companies
  7. Portal Hypertension - Therapeutics under Investigation by Universities/Institutes
  8. Portal Hypertension Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Portal Hypertension - Products under Development by Companies
  13. Portal Hypertension - Products under Investigation by Universities/Institutes
  14. Portal Hypertension - Companies Involved in Therapeutics Development
  • Conatus Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Galectin Therapeutics, Inc.
  • Genextra S.p.a.
  • LinXis B.V.
  • Mezzion Pharma Co. Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 12/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.